Blog Viewer

Trial of Dexamethasone for Chronic Subdural Hematoma

By Currents Editor posted 01-19-2021 13:42


New England Journal of Medicine (12/31/21) doi: 10.1056/NEJMoa2020473

Hutchinson, Peter J.; Edlmann, Ellie; Bulters, Diederik; et al.


Patients with chronic subdural hematoma who were treated with dexamethasone had fewer favorable outcomes and more adverse events at six months compared with those who received placebo, according to new research. The multicenter, randomized trial — which was conducted in the United Kingdom from August 2015 through November 2019 — included 748 adults with symptomatic chronic subdural hematoma. The participants had a mean age of 74 years, and 94% had undergone surgery to remove their hematomas during the index admission. In each group, 60% of the patients had a score of 1 to 3 on the modified Rankin Scale at admission. A modified intention-to-treat analysis involving 680 patients showed a favorable outcome — a score of 0 to 3 on the modified Rankin Scale at six months after randomization — in 83.9% patients (286 of 341) in the dexamethasone group and in 90.3% (306 of 339) of the placebo group. In all, 1.7% (6) patients in the dexamethasone group and 7.1% (25) in the placebo group had repeat surgery for recurrence for the hematoma. Adverse events were more frequent in the dexamethasone group compared with the placebo group, with serious adverse events occurring in 16.0% and 6.4%, respectively. Adverse events of special interest — including hyperglycemia leading to treatment or discontinuation of the trial regimen, new-onset diabetes, hyperosmolar hyperglycemic state, new-onset psychosis, and upper gastrointestinal adverse effects — were reported in 10.9% and 3.2% in the two groups, respectively. The risk of any infection was 6.4% in the dexamethasone arm vs. 1.1% in the placebo arm.


By Shweta Goswami, MD; Eunice J Lee, MD; Rachael Scott, PharmD, BCCCP; Naomi Niznick, MD; Sasha Yakhkind, MD; Pouya Ameli, MD, MS; and Marc Babi, MD The role of practice management education—an umbrella term to describe salary negotiation, billing and coding, law and malpractice, and so on—has been ...
By: NCS Research Operations Subcommittee: Caitlin Brown PharmD, Michelle Schober MD, Shraddha Mainali MD, Cassia Righy MD, Minjee Kim MD, Tom Lawson CNP, Jennifer Kim MD, PhD, Ruchi Jha MD Can you tell me a little about yourself and how you got involved in the Neurocritical Care Society?   I ...
Yasser B. Abulhasan, MBChB, FRCPC, FNCS, Chairman, Neurocritical Care-MENA Chapter of IPACCMS It was a great pleasure organizing the 2 nd Neurocritical Care Regional Meeting in the Middle East and Africa in conjunction with the 17 th edition of the Emirates Critical Care Conference (ECCC). The meeting ...